Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, Tsukuba, Japan.
QST Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
J Med Radiat Sci. 2022 Jun;69(2):198-207. doi: 10.1002/jmrs.551. Epub 2021 Oct 19.
To confirm the feasibility of hypofractionated proton beam therapy (PBT), we compared the acute adverse event rates and International Prostate Symptom Score (IPSS) in prostate cancer patients treated with hypofractionated versus conventionally fractionated (2.0 Gy relative biological effectiveness (RBE)/fraction) PBT.
We reviewed 289 patients with prostate cancer, of whom 73, 100, and 116 patients were treated with 2.0, 2.5, and 3.0 Gy (RBE)/fraction, respectively. The endpoints were acute genitourinary and gastrointestinal toxicities and the IPSS, evaluated up to 6 months after PBT initiation.
No significant differences were found in acute toxicity rates or the IPSS among the fractionation schedules. Diabetes mellitus, age, and androgen deprivation therapy were not identified as factors associated with the IPSS.
There were no significant differences in adverse events or quality of life among the three fractionation schedules early after PBT.
为了确认低分割质子束治疗（PBT）的可行性，我们比较了接受低分割（2.0Gy 相对生物效应（RBE）/分割）与常规分割（2.0Gy RBE/分割）PBT 的前列腺癌患者的急性不良事件发生率和国际前列腺症状评分（IPSS）。
我们回顾了 289 例前列腺癌患者，其中分别有 73、100 和 116 例患者接受了 2.0、2.5 和 3.0Gy（RBE）/分割的治疗。终点是 PBT 开始后 6 个月内的急性泌尿生殖和胃肠道毒性以及 IPSS。
在急性毒性发生率或 IPSS 方面，三种分割方案之间没有显著差异。糖尿病、年龄和雄激素剥夺治疗并未被确定为与 IPSS 相关的因素。
在 PBT 后早期，三种分割方案之间的不良事件或生活质量没有显著差异。
